Key Highlights

  • Qiagen (NYSE:QGEN) agreed on Wednesday, October 21, 2026 to a recommended all-cash takeover offer from EQT at EUR 46.50 per share, about a 40% premium.
  • The deal values Qiagen at about EUR 9.6 billion, or about USD 10.8 billion, in equity and about USD 12.1 billion including debt, with the purchase price payable entirely in cash.
  • Abu Dhabi Investment Authority and CPP Investments are co-investors alongside the EQT XI fund, and closing is targeted for mid-2027 after regulatory approvals.
  • Because the offer is set in euros and closing is many months away, the spread on the US-listed shares carries currency and timing risk as well as deal risk.

The Terms of the Offer

Qiagen (NYSE:QGEN), a Netherlands-based supplier of molecular testing products used to prepare samples and detect diseases such as tuberculosis, agreed on Wednesday, October 21, 2026 to a recommended voluntary all-cash public takeover offer from private equity firm EQT. The bidding vehicle, backed by the EQT XI fund, offers EUR 46.50 per share. That implies an equity value of about EUR 9.6 billion, or about USD 10.8 billion, and about USD 12.1 billion including debt. The price represents a premium of about 40%. Abu Dhabi Investment Authority and CPP Investments, the Canadian pension fund manager, are co-investors. Closing is targeted for mid-2027. Qiagen shares rose about 2% as reports of an imminent deal circulated ahead of the formal announcement.

How the Take-Private Math Works

For Qiagen (NYSE:QGEN), the offer replaces an uncertain market value with a fixed cash price, subject to completion. A private equity buyer typically funds such a deal with a mix of fund equity and borrowed money, then seeks to raise cash flow before selling or relisting the business years later. Co-investors such as sovereign and pension funds reduce the equity cheque EQT must write from its own fund. The difference between equity value of about USD 10.8 billion and enterprise value of about USD 12.1 billion reflects net debt the buyer assumes. For holders of the US-listed shares, the offer is fixed in euros, so the dollar value moves with the exchange rate. The merger arbitrage spread, the gap between the share price and the offer, prices that currency exposure, the time to mid-2027 and completion risk.

Risks and What to Watch

The first risk for Qiagen (NYSE:QGEN) holders is completion: the offer needs regulatory clearances and enough shareholder acceptances, and a long timeline to mid-2027 leaves room for delays. The second is financing cost, since US 10-year yields near 5.1% raise the price of the leveraged debt behind buyouts. The third is currency, as a weaker euro would cut the dollar value of the EUR 46.50 price. Analysts at Oddo BHF cut their price target for EQT to SEK 370 after the announcement, a reminder that the buyer also carries risk. Investors should watch the offer document and acceptance period, the Fed decision on Wednesday, October 28, 2026 and the midterm elections on Tuesday, November 3, 2026.

Where Things Stand

The answer is that EQT is paying EUR 46.50 a share, about a 40% premium, to take Qiagen (NYSE:QGEN) private with sovereign and pension co-investors, in a deal worth about USD 12.1 billion including debt. For shareholders, the remaining questions are timing, approvals and currency rather than business performance. The next catalysts are publication of the offer document, the Fed decision on October 28 and regulatory filings ahead of a mid-2027 close. Deal terms can change before completion, and this is not investment advice.